Nurix Therapeutics (NRIX)
(Delayed Data from NSDQ)
$24.02 USD
+0.94 (4.07%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $24.04 +0.02 (0.08%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Brokerage Reports
0 items in cart
Nurix Therapeutics, Inc. [NRIX]
Reports for Purchase
Showing records 1 - 16 ( 16 total )
Company: Nurix Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
NX-5948 Objective Response Rate Rises in Latest Data Cut; Raising PT to $26
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Nurix Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Nurix Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Nurix Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for NRIX 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Nurix Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Nurix Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Developing a Novel Class of Degraders With Seagen; Raising PT to $35
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Nurix Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
NX-2127 and NX-5948 Lymphoma Data; 2Q23 Financials; Lowering PT to $33
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Nurix Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Nurix Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Gilead Exercises Option For IRAK4 Degrader; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Nurix Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Numerous Catalysts in 2H23; F4Q22 Financials Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Nurix Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Financials; Several Data Releases Slated by YE22; Modulating PT to $53
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Nurix Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Equity Financing Announced; F2Q22 Financial Results; Modulating PT to $54
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Nurix Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
AACR Presentation Takeaways; 1Q22 Financials; Modulating PT to $60
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Nurix Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Nurix Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Protein Degradation to Power Cancer Treatment; Initiating at Buy and $62 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Nurix Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
|